Skip to main content

Advertisement

SpringerLink
Log in

The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 20 April 2012

Abstract

Background

To investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose.

Method

Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively.

Results

All 32 patients underwent laparotomy including 18 (56.3%) pancreaticoduodenectomy (PD), six (18.7%) segmental resection (SR), and eight bypass procedures. And R0 resections were obtained in 22 patients; the other ten procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 78.1% (25/32), 43.8% (14/32), and 18.8% (6/32), respectively; moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (20/20), 70.0% (14/20), and 30.0% (6/20), which were significantly higher than those (41.7% = 5/12, 0%, and 0%) in patients with palliative operation (P < 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05).

Conclusion

PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients especially for tumors of the distal duodenum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

PADC:

primary duodenal adenocarcinoma

PD:

pancreaticoduodenectomy

CT:

computed tomography

US:

ultrasonography

CA19-9:

CA19-9 antigen

ALP:

alkaline phosphates

FT-207:

ftorafur

References

  1. Alwmark A, Anderson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg. 1980;191(1):13–8.

    Article  PubMed  CAS  Google Scholar 

  2. Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology. 2007;54(73):129–34.

    PubMed  Google Scholar 

  3. Hu JX, Miao XY, Zhong DW, Dai WD, Liu W, Hu W. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology. 2006;53(72):858–62.

    PubMed  Google Scholar 

  4. Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P. Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases. Zhonghua Yi Xue Za Zhi. 2005;85(8):510–13.

    PubMed  Google Scholar 

  5. Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, et al. Duodenal adenocarcinoma. Cir Esp. 2005;77(4):208–12.

    Article  PubMed  Google Scholar 

  6. Saiura A, Yamamoto J, Yamaguchi T. Primary duodenal carcinoma. Gan To Kagaku Ryoho. 2004;31(3):327–30.

    PubMed  Google Scholar 

  7. Liu JF, Li A, Liu Q, Zhou JS, Sun JB, Li D. Surgical treatment of 475 patients with periampullary carcinoma. Zhonghua Zhong Zhong Liu Za Zhi. 2005;27(4):251–3.

    Google Scholar 

  8. Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.

    Article  PubMed  CAS  Google Scholar 

  9. Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127(5):557–60.

    Article  PubMed  CAS  Google Scholar 

  10. Small Intestine. In: American joint committee on cancer: manual for staging of cancer. Beahrs OH, Hason DE, Hutter RVP, Kennedy BJ, Editor. Philadelphia: JB Lippincott Co, 1992. p 69–73.

  11. Declore R, Thomas JH, Forster J. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166(12):626–31.

    Google Scholar 

  12. Lang H, Nadalin S, Raab R, Jahne J. Results of surgical therapy of primary adenocarcinoma of the duodenum. Chirurg. 1999;70(5):571–7.

    Article  PubMed  CAS  Google Scholar 

  13. Kazerooni EA, Quint LE, Francis IR. Duodenal neoplasm: predictive value of CT for determining malignancy and tumor resectability. AJR Am J Roentgenol. 1992;159(2):303–9.

    PubMed  CAS  Google Scholar 

  14. Jurisic D, Doko M, Glavan E, Rosko D, Vidovic D, Tomic K. Local recurrence of primary non-ampullary adenocarcinoma of duodenum after surgical treatment—a case report and a literature review. Coll Antropo. 2006;30(1):225–9.

    Google Scholar 

  15. Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.

    PubMed  CAS  Google Scholar 

  16. Bucher P, Gervaz P, Morel P. Long-term results of radical resection for locally advanced duodenal adenocarcinoma. Hepatogastroenterology. 2005;52(66):1727–9.

    PubMed  Google Scholar 

  17. Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg. 2004;21(5–6):434–8.

    Article  PubMed  CAS  Google Scholar 

  18. Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41.

    Article  PubMed  CAS  Google Scholar 

  19. Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinicopathological analysis. World J Gastroenterol. 2007;13(7):1108–11.

    PubMed  Google Scholar 

  20. Yang YM, Tian XD, Zhuang Y, Wang WH, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol. 2005;11(16):2456–61.

    PubMed  Google Scholar 

  21. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China

    Shao-Liang Han, Jun Cheng, Hong-Zhong Zhou, Qi-Qiang Zeng & Sheng-Hong Lan

Authors
  1. Shao-Liang Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-Zhong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qi-Qiang Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sheng-Hong Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shao-Liang Han.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s12029-012-9385-2

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, SL., Cheng, J., Zhou, HZ. et al. The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma. J Gastrointest Canc 41, 243–247 (2010). https://doi.org/10.1007/s12029-010-9160-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-010-9160-1

Keywords

Search

Navigation